Combined Immunotherapy and oral chemotherapy to prevent recurrence of hepatocellular carcinoma after hepatectomy: a prospective randomized open controlled study.

Trial Profile

Combined Immunotherapy and oral chemotherapy to prevent recurrence of hepatocellular carcinoma after hepatectomy: a prospective randomized open controlled study.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Capecitabine (Primary) ; Thymalfasin (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date changed from 1 Jun 2011 to 31 Dec 2011 as reported by Chinese Clinical Trial Register record.
    • 22 Nov 2011 Additional lead trial center identified as reported by Chinese Clinical Trial Register record.
    • 17 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top